Scott C. Schuyler |
||||
Appointments:Associate professor |
Lab:Yeast biochemistry& genetics lab |
|||
Education:Ph.D. |
School/Nation:Harvard University/USA |
|||
Tel: (03)211-8800 ext:3596 |
E-mail: schuyler@mail.cgu.edu.tw |
|||
Research website: https://scs03596.wixsite.com/scslab |
||||
研究室現有: 博士後研究員 人 |
博士班研究生 人 |
碩士班研究生 人 |
||
專任研究助理 4 人 |
大學部專題生 人 |
|
||
Mitotic Spindle Checkpoint The mitotic spindle checkpoint prevents chromosome loss. I want to understand how this checkpoint regulates chromosome segregation during eukaryotic cell division, primarily by studying how the spindle checkpoint inhibits the cell cycle regulator the Anaphase-Promoting Complex (APC). Yeast genetics, cell biology, and biochemistry in combination are powerful tools for exploring the molecular roles of protein complexes. In the lab, I use my training in these fields to develop biochemical, cell biological and genetic approaches to ask how the mitotic spindle checkpoint functions to inhibit APC.
|
||||
One of the most successful chemotherapeutic agents has been mitotic poisons, such as microtubule poisons like paclitaxel. Although the exact cellular mechanisms leading to cancer cell death are unclear, mitotic poisons are thought to act by creating a delay in mitosis, which in turn leads to cells undergoing apoptosis.
Cancer cells may not respond to mitotic poison-based treatments in the clinic, or may develop resistance to the therapy. Although the cellular mechanisms explaining mitotic poison resistance in each cancer type and each cancer patient remains unclear, ultimately the mitotic poison resistance allows the cancer cells to escape the delay in cell cycle progression in mitosis and under go ‘mitotic slippage’, and re-enter the cell cycle rather than undergoing apoptotic cell death.
Figure 1. Cancer cell survival requires the APC/CCdc20 enzyme for ‘mitotic slippage’ and continued cell division to avoid apoptotic cell death. Currently, there are no known APC/CCdc20 enzyme drug inhibitors. ‘Mitotic slippage’ requires the activity of the master cell cycle regulator, an E3-Ubiquitin Ligase, called the Anaphase-Promoting Complex/Cyclosome (APC/C), and the essential mitotic co-factor Cdc20 (Cell Division Cycle 20) (Huang, et al., 2010a; Schuyler, et al., 2012). This knowledge has led to a recent set of studies to investigate how to prevent ‘mitotic slippage’, and thus promote cancer cell apoptosis.
|
||||
In the lab, we have employed the simple eukaryote budding yeast to discover novel and unique peptides inhibitors that can target the APC/C enzyme activity. We have also demonstrated that our peptide inhibitors makes cells specifically sensitive to an anti-mitotic microtubule poison in vivo when over-expressed in the cell.
Our long-term goal is the creation of a new class of anti-cancer agents specifically targeting APC/CCdc20 activity that can be used in combination with anti-mitotic drug cancer therapies. We expect two primary benefits: 1. A new peptide inhibitor against APC/CCdc20 activity will be developed and characterized. 2. The initial characterization using human colon cancer cells of a potentially novel combinatorial therapeutic agent will have been completed. |
||||
Publications:
|